February 3, 2017
FDA approves Bristol-Myers’s Opdivo for urothelial bladder cancer
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
Pharmaceuticals, Biotechnology and Life Sciences
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).